Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

CEDARS-SINAI Seeks Participants With Type 2 Diabetes For Study Of Implantable Devices

25.03.2008
Cedars-Sinai Medical Center is seeking participants with type 2 diabetes for a randomized, controlled clinical study evaluating an implantable device that delivers electrical impulses to the stomach.

The study is part of a national clinical trial to determine the safety and efficacy of the device for possible treatment for overweight patients with type 2 diabetes.

Participants must be 18 to 70 years of age with type 2 diabetes and have a body mass index (BMI) between 28 and 45*. Those enrolled will undergo a laparoscopic procedure for implantation of the device, which requires an overnight stay at the hospital.

The device consists of a pulse generator that is implanted under the skin near the stomach and leads that are implanted in the gastric muscle. The treatment is based on a new technology called Gastric Contractility Modulation (GCM) that is designed to sense naturally occurring electrical activity of the stomach in real time and automatically apply electrical stimulation treatment during meal times.

The primary objective of the study is to evaluate the safety and efficacy of the device based on improvement in blood sugar levels (HbA1c), but impact on weight loss, blood pressure and other clinical and metabolic benchmarks will also be studied. The device will be implanted for at least 12 months and up to three years. Study subjects will be randomized into control or treatment groups, evaluated weekly and monthly at the beginning of the study, and then periodically for the remainder of the study.

The national epidemic of type 2 diabetes, most often associated with being overweight, continues to accelerate and affects more than 20 million Americans. About one million people are diagnosed with the metabolic disease annually.

Participants will receive all testing and study-related medical care at no cost and will be compensated for study-related expenses. After the first 12 months, participants will receive semi-annual evaluations for the remaining 2 years until a determination of safety and efficacy is made by the FDA. All information gathered during the study will be kept confidential.

The study is sponsored by MetaCure (USA), Inc., the company that developed the device, which is called the TANTALUS® system.

For more information, please call Colleen Sam at (310) 423-3779 or visit www.cedars-sinai.edu

*Body Mass Index (BMI) is a measure of body fat based on height and weight. Tables and calculation tools can be found at the National Heart Lung and Blood Institute website, which is www.nhlbisupport.com/bmi/

Simi Singer | Cedars-Sinai Medical Center
Further information:
http://www.cshs.org
http://www.cedars-sinai.edu
http://www.nhlbisupport.com/bmi/

More articles from Studies and Analyses:

nachricht Disarray in the brain
18.12.2017 | Universität zu Lübeck

nachricht Amputees can learn to control a robotic arm with their minds
28.11.2017 | University of Chicago Medical Center

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Error-free into the Quantum Computer Age

A study carried out by an international team of researchers and published in the journal Physical Review X shows that ion-trap technologies available today are suitable for building large-scale quantum computers. The scientists introduce trapped-ion quantum error correction protocols that detect and correct processing errors.

In order to reach their full potential, today’s quantum computer prototypes have to meet specific criteria: First, they have to be made bigger, which means...

Im Focus: Search for planets with Carmenes successful

German and Spanish researchers plan, build and use modern spectrograph

Since 2016, German and Spanish researchers, among them scientists from the University of Göttingen, have been hunting for exoplanets with the “Carmenes”...

Im Focus: First-of-its-kind chemical oscillator offers new level of molecular control

DNA molecules that follow specific instructions could offer more precise molecular control of synthetic chemical systems, a discovery that opens the door for engineers to create molecular machines with new and complex behaviors.

Researchers have created chemical amplifiers and a chemical oscillator using a systematic method that has the potential to embed sophisticated circuit...

Im Focus: Long-lived storage of a photonic qubit for worldwide teleportation

MPQ scientists achieve long storage times for photonic quantum bits which break the lower bound for direct teleportation in a global quantum network.

Concerning the development of quantum memories for the realization of global quantum networks, scientists of the Quantum Dynamics Division led by Professor...

Im Focus: Electromagnetic water cloak eliminates drag and wake

Detailed calculations show water cloaks are feasible with today's technology

Researchers have developed a water cloaking concept based on electromagnetic forces that could eliminate an object's wake, greatly reducing its drag while...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

AKL’18: The opportunities and challenges of digitalization in the laser industry

07.12.2017 | Event News

 
Latest News

Single-photon detector can count to 4

18.12.2017 | Information Technology

Quantum memory with record-breaking capacity based on laser-cooled atoms

18.12.2017 | Physics and Astronomy

How much soil goes down the drain -- New data on soil lost due to water

18.12.2017 | Agricultural and Forestry Science

VideoLinks
B2B-VideoLinks
More VideoLinks >>>